Volume 15, Issue 4, Pages (April 2014)

Slides:

Advertisements

Similar presentations

Outcome of chemotherapy in synovial sarcoma (sys) patients (pts): review of 15 clinical trials from EORTCc involving advanced sys compared to other Soft.

Advertisements

Crohn's disease Prof Daniel C Baumgart, MD, Prof William J Sandborn, MD The Lancet Volume 380, Issue 9853, Pages (November 2012) DOI: /S (12)

Volume 17, Issue 11, Pages (November 2016)

Volume 14, Issue 12, Pages (November 2013)

Volume 370, Issue 9586, Pages (August 2007)

Volume 14, Issue 4, Pages (April 2013)

Volume 16, Issue 8, Pages (August 2015)

Volume 385, Issue 9980, Pages (May 2015)

Volume 385, Issue 9980, Pages (May 2015)

Volume 379, Issue 9824, Pages (April 2012)

Volume 17, Issue 5, Pages (May 2016)

Volume 364, Issue 9440, Pages (September 2004)

Volume 16, Issue 2, Pages (February 2015)

Volume 351, Issue 9110, Pages (April 1998)

Volume 370, Issue 9605, Pages (December 2007)

Volume 357, Issue 9257, Pages (March 2001)

Volume 8, Issue 3, Pages (March 2007)

Volume 12, Issue 11, Pages (October 2011)

Volume 376, Issue 9747, Pages (October 2010)

Jarrod D. Predina, BA, Matthew M. Puc, MD, Meredith R

Volume 388, Issue 10058, Pages (November 2016)

Volume 15, Issue 6, Pages (May 2014)

Erlotinib or Docetaxel for Second-Line Treatment of Non-small Cell Lung Cancer: A Real-World Cost-Effectiveness Analysis Ian Cromwell, MSc, Kimberly.

Volume 14, Issue 4, Pages (April 2013)

Volume 377, Issue 9783, Pages (June 2011)

Volume 389, Issue 10076, Pages (April 2017)

Volume 15, Issue 8, Pages (July 2014)

Volume 15, Issue 4, Pages (April 2014)

Volume 376, Issue 9757, Pages (December 2010)

Aspirin in the prevention of cancer – Author's reply

Volume 374, Issue 9707, Pages (December 2009)

Volume 15, Issue 4, Pages (April 2014)

The CONSORT statement: revised recommendations for improving the quality of reports of parallel-group randomised trials David Moher, MSc, Kenneth F Schulz,

Volume 14, Issue 7, Pages (June 2013)

Volume 15, Issue 4, Pages (April 2014)

Volume 14, Issue 8, Pages (July 2013)

Volume 14, Issue 8, Pages (July 2013)

Volume 12, Issue 7, Pages (July 2011)

Volume 18, Issue 3, Pages (March 2017)

Volume 379, Issue 9812, Pages (January 2012)

Jarrod D. Predina, BA, Matthew M. Puc, MD, Meredith R

Volume 16, Issue 8, Pages (August 2015)

Volume 6, Issue 6, Pages (June 2005)

Volume 14, Issue 6, Pages (May 2013)

Volume 13, Issue 5, Pages (May 2012)

Volume 20, Issue 1, Pages (January 2019)

Volume 14, Issue 11, Pages (October 2013)

Volume 385, Issue 9962, Pages (January 2015)

Volume 15, Issue 8, Pages (July 2014)

Volume 388, Issue 10058, Pages (November 2016)

Volume 371, Issue 9627, Pages (May 2008)

Volume 378, Issue 9786, Pages (July 2011)

Volume 9, Issue 4, Pages (April 2008)

Volume 15, Issue 6, Pages (May 2014)

Volume 5, Issue 4, Pages (April 2018)

Volume 17, Issue 10, Pages (October 2016)

Volume 373, Issue 9658, Pages (January 2009)

Volume 14, Issue 8, Pages (July 2013)

Volume 19, Issue 10, Pages (October 2018)

Volume 15, Issue 6, Pages (May 2014)

ACST: which subgroups will benefit most from carotid endarterectomy?

Volume 376, Issue 9757, Pages (December 2010)

Volume 18, Issue 10, Pages (October 2017)

Volume 375, Issue 9715, Pages (February 2010)

Volume 376, Issue 9747, Pages (October 2010)

Volume 14, Issue 9, Pages (August 2013)

Volume 13, Issue 7, Pages (July 2014)

Volume 12, Issue 1, Pages (January 2011)

Outcomes of patients with childhood B-cell precursor acute lymphoblastic leukaemia with late bone marrow relapses: long-term follow-up of the ALLR3 open-label.

Volume 14, Issue 7, Pages (June 2013)

Presentation transcript:

Volume 15, Issue 4, Pages 415-423 (April 2014) Doxorubicin alone versus intensified doxorubicin plus ifosfamide for first-line treatment of advanced or metastatic soft-tissue sarcoma: a randomised controlled phase 3 trial Prof Ian Judson, MD, Prof Jaap Verweij, PhD, Prof Hans Gelderblom, PhD, Prof Jörg T Hartmann, MD, Prof Patrick Schöffski, MPH, Prof Jean-Yves Blay, PhD, J Martijn Kerst, PhD, Prof Josef Sufliarsky, MD, Prof Jeremy Whelan, MD, Prof Peter Hohenberger, MD, Anders Krarup-Hansen, MD, Prof Thierry Alcindor, MD, Sandrine Marreaud, MD, Saskia Litière, PhD, Catherine Hermans, Prof Cyril Fisher, DSc, Prof Pancras C W Hogendoorn, PhD, Prof A Paolo dei Tos, MD, Prof Winette T A van der Graaf, PhD The Lancet Oncology Volume 15, Issue 4, Pages 415-423 (April 2014) DOI: 10.1016/S1470-2045(14)70063-4 Copyright © 2014 Elsevier Ltd Terms and Conditions

Figure 1 Trial profile *One of whom started treatment but did not follow the allocated approach. The Lancet Oncology 2014 15, 415-423DOI: (10.1016/S1470-2045(14)70063-4) Copyright © 2014 Elsevier Ltd Terms and Conditions

Figure 2 Kaplan-Meier curves for overall survival (A) and progression-free survival (B) HR=hazard ratio. The Lancet Oncology 2014 15, 415-423DOI: (10.1016/S1470-2045(14)70063-4) Copyright © 2014 Elsevier Ltd Terms and Conditions

Figure 3 Progression-free survival by subgroup The Lancet Oncology 2014 15, 415-423DOI: (10.1016/S1470-2045(14)70063-4) Copyright © 2014 Elsevier Ltd Terms and Conditions